Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma

Molecular Carcinogenesis

Volumn 54, Issue 1, 2015, Pages 9-23

  Stewart, Jerry E ^a   Ma, Xiaojie ^b   Megison, Michael ^a   Nabers, Hugh ^a   Cance, William G ^c   Kurenova, Elena V ^c   Beierle, Elizabeth A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

C4; FAK; FLT 4; SK N AS; SK N BE(2)

Indexed keywords

CHLOROPYRAMINE; DOXORUBICIN; FOCAL ADHESION KINASE; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; ETHYLENEDIAMINE DERIVATIVE; FOCAL ADHESION KINASE 1; PTK2 PROTEIN, HUMAN; VEGFR3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENICITY; CELL ADHESION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; ANIMAL; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOXORUBICIN; DRUG SYNERGISM; ETHYLENEDIAMINES; FEMALE; FOCAL ADHESION KINASE 1; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEUROBLASTOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84914676536     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22070     Document Type: Article

References (49)

1. Cotterill S, Parker L, More L, Craft A. Neuroblastoma: Changing incidence and survival in young people aged 0-24 years. A report from the North of England Young Persons' Malignant Disease Registry. Med Pediatr Oncol 2001; 36:231-234.
2. Hanks S, Polte T. Signaling through focal adhesion kinase. Bioessays 1977; 19:137-145.
3. Zachary I. Focal adhesion kinase. Int J Biochem Cell Biol 1997; 29:929-934.
4. Gabarra-Niecko V, Schaller M, Dunty J. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003; 22:359-374.
5. Schaller M, Borgman C, Cobb B, Vines R, Reynolds A, Parsons J. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 1992; 89:5192-5196.
6. Lipinski C, Tran N, Menashi E, et al. The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia 2005; 7:435-445.
7. Xu L, Yang X, Bradham C, et al. The focal adhesion kinase suppresses transformation associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J Biol Chem 2000; 275:30597-30604.
8. Xu L, Yang X, Craven R, Cance W. The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ 1998; 9:999-1005.
9. Xu L, Owens L, Sturge G, et al. Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ 1996; 7:413-418.
10. Golubovskaya V, Beviglia L, Xu L, Earp Hr, Craven R, Cance W. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor mediated apoptosis in human breast cancer cells. J Biol Chem 2002; 277:38978-38987.
11. Halder J, Landen CJ, Lutgendorf S, et al. Focal adhesion kinase silencing augments docetaxel mediated apoptosis in ovarian cancer cells. Clin Cancer Res 2005; 11:8829-8836.
12. Shi Q, Hjelmeland AB, Keir ST, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 2007; 46:488-496.
13. Beierle E, Massoll N, Hartwich J, et al. Focal adhesion kinase expression in human neuroblastoma: Immunohistochemical and real-time PCR analyses. Clin Cancer Res 2008; 14:3299-3305.
14. Beierle E, Trujillo A, Nagaram A, et al. N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem 2007; 282:12503-12516.
15. Beierle EA, Trujillo A, Nagaram A, Golubovskaya VM, Cance WG, Kurenova EV. TAE226 inhibits human neuroblastoma cell survival. Cancer Invest 2008; 26:145-151.
16. Beierle E, Ma X, Stewart J, et al. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle 2010; 9:1005-1015.
17. Liu X, Sun X, Wu J. Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol 2004; 10:352-355.
18. van Iterson V, Leidenius M, von Smitten K, Bono P, Heikkilä P. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. Am J Clin Pathol 2007; 128:759-766.
19. Saintigny P, Kambouchner M, Ly M, et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: Concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer 2007; 58:205-213.
20. Herrmann E, Eltze E, Bierer S, et al. VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: Relationships to clinicopathological parameters and long-term survival. Anticancer Res 2007; 27:3127-3133.
21. Kurenova EV, Hunt DL, He D, et al. Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo. Cell Cycle 2009; 8:2266-2280.
22. Laakkonen P, Waltari M, Holopainen T, et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 2007; 67:593-599.
23. Beierle EA, Dai W, Langham MJ, Copeland ER, Chen M. VEGF receptors are differentially expressed by neuroblastoma cells in culture. J Pediatr Surg 2003; 38:514-521.
24. Beierle EA, Dai W, Langham MJ, Copeland E, Chen M. Expression of VEGF receptors in cocultured neuroblastoma cells. J Surg Res 2004; 119:56-65.
25. Lagodny J, Jüttner E, Kayser G, Niemeyer C, Rössler J. Lymphangiogenesis and its regulation in human neuroblastoma. Biochem Biophys Res Commun 2007; 352:571-577.
26. Rössler J, Monnet Y, Farace F, et al. The selective VEGFR 1-3 in hibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. Int J Cancer 2011; 128:2748-2758.
27. Garces C, Kurenova E, Golubovskaya V, Cance W. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res 2006; 66:1446-1454.
28. Kurenova E, Hunt D, He D, Magis A, Ostrov D, Cance W. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem 2009; 52:4716-4724.
29. Beierle EA, Ma X, Stewart JE, Megison M, Cance WG, Kurenova EV. Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines. Mol Carcinog 2012; doi: 10.1002/mc.21969. [Epub ahead of print].
30. Manders EMM, Verbeek FJ, Aten JA. Measurement of colocalization of objects in dual-color confocal images. J Microsc 1993; 169:375-382.
31. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124:619-626.
32. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996; 134:793-799.
33. Chen HC, Guan JL. The association of focal adhesion kinase with a 200-kDa protein that is tyrosine phosphorylated in response to platelet-derived growth factor. Eur J Biochem 1996; 235:495-500.
34. Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000; 2:249-256.
35. Liu W, Bloom D, Cance W, Kurenova E, Golubovskaya V, Hochwald S. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008; 29:1096-1107.
36. Chen SY, Chen HC. Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol Cell Biol 2006; 26:5155-5167.
37. Golubovskaya VM, Finch R, Cance WG. Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. J Biol Chem 2005; 80:25008-25021.
38. Ji P, Sun D, Wang H, Bauzon F, Zhu L. Disrupting Skp2-cyclin A interaction with a blocking peptide induces selective cancer cell killing. Mol Cancer Ther 2007; 6:684-691.
39. Dasgupta P, Sun J, Wang S, et al. et al. Disruption of the Rb-Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol 2004; 24:9527-9541.
40. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-848.
41. Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009; 15:750-756.
42. Manero F, Gautier F, Gallenne T, et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 2006; 66:2757-2764.
43. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced stage disease. Science 1984; 224:1121-1124.
44. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313:1111-1116.
45. Uçar K, Seeger R, Challita P, et al. Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector. Cancer Gene Ther 1995; 2:171-181.
46. Nguyen T, Hocker JE, Thomas W, et al. Combined RAR alpha- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells. Biochem Biophys Res Commun 2003; 302:462-468.
47. Weinstein IB. Cancer. Addiction to oncogenes-The Achilles heal of cancer. Science 2002; 297:63-64.
48. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun 2003; 311:786-792.
49. Chen YY, Wang ZX, Chang PA, et al. Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance. Cancer Sci 2009; 100:1708-1713.